Odyssey Health files patent for intranasal brain-drug device; Phase I study successful

Odyssey Health, Inc.

Filed US/global patent for breath-propelled intranasal brain-drug delivery device (Nasal Device).
Phase I study of PRV-002 concussion drug via Nasal Device completed; well-tolerated in 40 healthy volunteers.
No Nasal Device failures documented; device deposits drug deep into nasal cavity for direct CNS diffusion.
CEO Michael Redmond cited advantage of direct brain delivery with fewer side effects for neurological treatments.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.